Symptom severity in patients with confirmed COVID-19 diagnosis
or exposure
Next, we compared the subgroup of patients comprised of those with a
laboratory confirmed COVID-19 infection history based on PCR testing, or
other antibody testing performed in a clinical context, or those with
high-risk COVID-19 exposures, including to individuals with documented
COVID-19 infection or with symptoms highly suspicious for COVID-19
infection (n=164 for dupilumab, n=26 for other systemics, n=116 for
limited/no treatment; Table 3; Figure 2). Similar to the previous
logistic regression model results, non-dupilumab systemic treatment was
significantly associated with moderate-to-severe symptoms relative to
treatment with dupilumab (OR=13.79; p=0.002; Table 4A). Additionally,
being on limited/no treatment was also significantly associated with
moderate-to-severe symptoms relative to dupilumab (OR=2.44; p=0.05;
Table 4B). BMI was a significant covariate of moderate-to-severe
symptoms across all systemic treatment groups in this known
infection/high-risk exposure group (p=0.005; Table 4A).
In patients with known COVID-19 infection or high-risk exposure, being
on non-dupilumab, systemic therapies was significantly associated with
symptomatology relative to being on dupilumab (OR=2.97; p=0.03, Table
4C). Similar to the entire cohort, there were also no differences in
predicting symptoms among high-risk exposure patients on dupilumab
relative to the limited/no treatment group (Table 4D).